MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$241,071K
EPS
-$2.85
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
221,377
24,365
27,417*
31,450
General and administrative
24,663
20,975
11,372*
9,681
Total operating expenses
246,040
45,340
38,788
41,131
Loss from operations
-246,040
-45,340
-38,788*
-41,131
Interest income, net
4,956
5,996
4,450*
4,195
Other income (expense)
13
5
-3*
4
Total other income, net
4,969
6,001
4,447*
4,199
Net loss
-241,071
-39,339
-34,342
-36,932
Basic EPS
-2.85
-0.47
-0.513
-0.52
Diluted EPS
-2.85
-0.47
-0.513
-0.52
Basic Average Shares
84,727,282
82,834,752
66,923,264
70,594,504
Diluted Average Shares
84,727,282
82,834,752
66,923,264
70,594,504
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Interest income, net
$4,956K
(42.66%↑ Y/Y)
Other income
(expense)
$13K
(750.00%↑ Y/Y)
Net loss
-$241,071K
(-457.08%↓ Y/Y)
Total other income,
net
$4,969K
(43.12%↑ Y/Y)
Loss from operations
-$246,040K
(-426.33%↓ Y/Y)
Total operating
expenses
$246,040K
(426.33%↑ Y/Y)
Research and development
$221,377K
(478.34%↑ Y/Y)
General and
administrative
$24,663K
(191.25%↑ Y/Y)
Buy us a coffee
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)